Abarelix

• Description:

  Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.

• Product Name Alternative:

  R3827; PPI 149

• UNSPSC:

  12352209

• Hazard Statement:

  H302, H312, H332

• Target:

  GnRH Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/Abarelix.html

• Purity:

  99.72

• Solubility:

  H2O : 42 mg/mL (ultrasonic; warming) |DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCCNC(C)C)NC([C@H](CC(C)C)NC([C@@H](CC(N)=O)NC([C@H](CC2=CC=C(C=C2)O)N(C([C@H](CO)NC([C@@H](CC3=CC=CN=C3)NC([C@@H](CC4=CC=C(Cl)C=C4)NC([C@@H](CC5=CC=C6C=CC=CC6=C5)NC(C)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)CCC1)=O

• Molecular Formula:

  C72H95ClN14O14

• Molecular Weight:

  1416.06

• Precautions:

  H302, H312, H332

• References & Citations:

  [1]Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70 (4) :580-7.|[2]Kirby RS, et al. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104 (11) :1580-4.|[3]Debruyne F, et al. Abarelix for injectable suspension: first-in-class releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2 (6) :677-96.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  Launched

• CAS Number:

  [183552-38-7]